U.S., Sept. 4 -- ClinicalTrials.gov registry received information related to the study (NCT07153055) titled 'Phase I/II Trial of Lurbinectedin With Osimertinib in Transformed Small Cell Lung Cancer' on Aug. 26.
Brief Summary: This open-label, Phase I/II trial is studying the safety and effectiveness of an experimental drug combination, lurbinectedin with osimertinib, against a rare type of cancer known as transformed small cell lung cancer (SCLC).
Study Start Date: Nov., 2025
Study Type: INTERVENTIONAL
Condition:
Small Cell Lung Cancer ( SCLC )
Transformed Small Cell Lung Cancer
Intervention:
DRUG: Lurbinectedin
Two lurbinectedin does of 3.2 mg/m2 or 2.6 mg/m2. The initial starting dose is 3.2 mg/m2. Patients will receive lurbinecte...